Literature DB >> 18091300

Elevated intraocular pressure and myopic shift linked to topiramate use.

Christian P Guier1.   

Abstract

PURPOSE: The purpose of this report is to describe acute myopia as an ocular adverse reaction to topiramate (Topamax, Ortho-McNeil, Raritan, NJ) and discuss the importance of recognizing this syndrome.
METHODS: Retrospective case report and brief review of the literature.
RESULTS: A 27-year-old female patient developed decreased vision in both eyes due to acute myopia 2 weeks of after initiating therapy with topiramate. Emergency department evaluation revealed visual acuities of 20/400 right eye and 20/200 left eye. Intraocular pressures were 33 mm Hg right eye and 26 mm Hg left eye. The anterior chambers were shallow. Retinal striae were present in the maculae. The patient stated no previous need for optical correction. However, after initiating treatment with topiramate, she refracted to approximately -5.00 D bilaterally. Ultrasound testing revealed that the patient had suprachoroidal effusions in both eyes. The symptoms and clinical findings resolved completely with discontinuation of topiramate, administration of topical atropine 1% and prednisolone acetate 1%.
CONCLUSIONS: An acute myopic shift may be the presenting sign of an idiosyncratic drug reaction that can include secondary bilateral angle closure glaucoma. This condition can occur in patients who do not have a history of anterior chamber abnormalities. Recognizing this condition and discontinuing the use of the causative drug may prevent angle closure and associated vision loss.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18091300     DOI: 10.1097/OPX.0b013e31815b9e38

Source DB:  PubMed          Journal:  Optom Vis Sci        ISSN: 1040-5488            Impact factor:   1.973


  12 in total

1.  A 53-year-old woman with a severe headache, bilateral eye pain, blurred vision, and photophobia.

Authors:  Pedro Barros; Liliana Paris; Joana Martins; Paula Tenedorio
Journal:  Digit J Ophthalmol       Date:  2011-08-28

2.  Acute cilio-choroidal effusion due to acetazolamide: unusual posterior involvement (OCT aspects).

Authors:  R Malagola; R Giannotti; L Pattavina; L Arrico
Journal:  Eye (Lond)       Date:  2013-04-05       Impact factor: 3.775

Review 3.  Topiramate in the new generation of drugs: efficacy in the treatment of alcoholic patients.

Authors:  Bankole A Johnson; Nassima Ait-Daoud
Journal:  Curr Pharm Des       Date:  2010       Impact factor: 3.116

4.  Acute-onset bilateral myopia and ciliochoroidal effusion induced by hydrochlorothiazide.

Authors:  Young-Rae Roh; Se Joon Woo; Kyu Hyung Park
Journal:  Korean J Ophthalmol       Date:  2011-05-24

5.  Bilateral angle-closure glaucoma in a young female receiving cabergoline: a case report.

Authors:  Hasan Razmjoo; Leila Rezaei; Alireza Dehghani; Alireza Peyman; Mohammadreza Akhlaghi
Journal:  Case Rep Ophthalmol       Date:  2011-01-21

6.  Glaucoma: Adverse event on use of topiramate in alcohol de-addiction.

Authors:  Keshava Pai; Pooja Rajashekaran
Journal:  Indian J Psychiatry       Date:  2011-04       Impact factor: 1.759

7.  Topiramate and the vision: a systematic review.

Authors:  Mohammad-Ali Abtahi; Seyed-Hossein Abtahi; Farhad Fazel; Peyman Roomizadeh; Masoud Etemadifar; Keivan Jenab; Mojtaba Akbari
Journal:  Clin Ophthalmol       Date:  2012-01-12

Review 8.  Acute myopia and angle closure glaucoma from topiramate in a seven-year-old: a case report and review of the literature.

Authors:  Yuna Rapoport; Nancy Benegas; Rachel W Kuchtey; Karen M Joos
Journal:  BMC Pediatr       Date:  2014-04-09       Impact factor: 2.125

9.  Topiramate-Induced Acute Myopia, Diplopia, and Photosensitivity: A Case Report.

Authors:  Murat Kocamaz; Onur Karadag
Journal:  Beyoglu Eye J       Date:  2019-02-20

10.  Acetazolamide-induced cilio-choroidal effusion after cataract surgery: unusual posterior involvement.

Authors:  Romualdo Malagola; Loredana Arrico; Rossella Giannotti; Luigi Pattavina
Journal:  Drug Des Devel Ther       Date:  2013-01-23       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.